The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma

BACKGROUND: Targeted approaches for inhibiting epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases (RTKs) in glioblastoma (GBM) have led to therapeutic resistance and little clinical benefit, raising the need for the development of alternative strategies. Endogenous LRIG1 (Le...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Neirinckx, Virginie, Hau, Ann-Christin, Schuster, Anne, Fritah, Sabrina, Tiemann, Katja, Klein, Eliane, Nazarov, Petr V, Matagne, André, Szpakowska, Martyna, Meyrath, Max, Chevigné, Andy, Schmidt, Mirko H H, Niclou, Simone P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Basic and Translational Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212925/
https://ncbi.nlm.nih.gov/pubmed/32642659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz024
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak